Subjects: Economics, Pharmaceutical / Copyright: Public domain - Digital Collections - National Library of Medicine Search Results

Start Over Subjects Economics, Pharmaceutical ✖ Copyright Public domain ✖

1. The Medicaid Drug Rebate Program: the basics

Publication:: Washington, D.C. : George Washington University, [2009]
Subject(s):: Drug Costs
Economics, Pharmaceutical
Medicaid -- economics
Health Expenditures
State Government
Humans
United States
Centers for Medicare & Medicaid Services (U.S.)

2. The prescription drug safety net: access to pharmaceuticals for the uninsured

Publication:: Washington, D.C. : George Washington University, [2007]
Subject(s):: Health Services Accessibility
Medical Assistance
Pharmaceutical Services
Uncompensated Care
Adult
Charities
Drug Industry
Drug Prescriptions -- economics
Economics, Pharmaceutical
Government Programs
HIV Infections -- drug therapy
Insurance, Pharmaceutical Services -- statistics & numerical data
Medically Uninsured
Middle Aged
Physician's Role
Practice Patterns, Physicians'
Humans
United States
United States. Health Resources and Services Administration.

3. Drug discount program: update on agency efforts to improve 340B program oversight : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives

Publication:: Washington, D.C. : U.S. Government Accountability Office, July 18, 2017
Subject(s):: Government Regulation
Insurance, Pharmaceutical Services -- economics
Medicaid -- economics
Contract Services
Economics, Pharmaceutical
Forecasting
Government Programs -- statistics & numerical data
Insurance, Health, Reimbursement
Pharmacies -- statistics & numerical data
Pharmacies -- trends
Humans
United States
United States. Health Resources and Services Administration.

4. Research and development in the pharmaceutical industry

Author(s):: Austin, David, author
Hayford, Tamara, author
Publication:: [Washington, DC] : Congressional Budget Office, April 2021
Subject(s):: Drug Development -- economics
Drug Industry -- economics
Research -- economics
Economics, Pharmaceutical
United States

5. Prescription Drug User Fee Act waivers, reductions, and refunds for drug and biological products

Publication:: Silver Spring, MD : Center for Drug Evaluation and Research, October 2019
Subject(s):: Drug Approval -- economics
Drug Approval -- legislation & jurisprudence
Investigational New Drug Application -- legislation & jurisprudence
Diffusion of Innovation
Economics, Pharmaceutical
Orphan Drug Production -- economics
Public Health
Small Business
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.
United States.

6. Drug discount program: status of agency efforts to improve 340B program oversight : testimony before the Committee on Health, Education, Labor, and Pensions, U.S. Senate

Publication:: Washington, DC : United States Government Accountability Office, May 15, 2018
Subject(s):: Drug Costs
Economics, Pharmaceutical
Government Regulation
Medicaid -- economics
United States
United States. Health Resources and Services Administration.

7. Drug discount program: federal oversight of compliance at 340B contract pharmacies needs improvement : report to Congressional requesters

Publication:: Washington, DC : United States Government Accountability Office, June 2018
Subject(s):: Drug Costs
Economics, Pharmaceutical
Pharmacies -- economics
Contract Services
United States
United States. Health Resources and Services Administration.

8. Drug discount program: improvements needed in federal oversight of compliance at 340B contract pharmacies : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives

Publication:: Washington, DC : United States Government Accountability Office, July 11, 2018
Subject(s):: Drug Costs
Economics, Pharmaceutical
Pharmacies -- economics
Contract Services
Government Regulation
United States
United States. Health Resources and Services Administration.

9. One percent of drugs with Medicaid reimbursement were not FDA-approved

Publication:: [Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, May 2019
Subject(s):: Drug Approval
Insurance, Health, Reimbursement -- economics
Insurance, Health, Reimbursement -- statistics & numerical data
Medicaid -- economics
Medicaid -- statistics & numerical data
Economics, Pharmaceutical
Fraud -- prevention & control
Prescription Drugs -- economics
Humans
United States
United States. Food and Drug Administration.

10. Medicare Part B drug payments: impact of price substitutions based on 2017 average sales prices

Publication:: [Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2019
Subject(s):: Cost Control
Cost Savings
Drug Costs
Insurance, Health, Reimbursement
Medicare Part B -- economics
Reimbursement Mechanisms
Economics, Pharmaceutical
Humans
United States
Centers for Medicare & Medicaid Services (U.S.)